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Abstract: The Systemic Immune-Inflammation Index (SII) is an important marker of immune
function, defined as the product of neutrophil-to-lymphocyte ratio (NLR) and platelet count (P).
Higher baseline SII levels have been associated with improved survival in various types of cancers,
including lung cancer. Data were obtained from PROCLAIM, a randomized phase III trial comparing
two different chemotherapy regimens pemetrexed + cisplatin (PEM) vs. etoposide + cisplatin (ETO),
in combination with radiotherapy (RT) for the treatment of stage III non-squamous non-small cell
lung cancer (NSCLC). We aimed to determine if SII measured at the mid-treatment window for RT
(weeks 3–4) is a significant predictor of survival, and if the effect of PEM vs. ETO differs by quartile
(Q) level of SII. Hazard-ratios (HR) for survival were estimated using a proportional hazards model,
accounting for the underlying correlated structure of the data. A total of 548 patients were included
in our analysis. The median age at baseline was 59 years. Patients were followed for a median of
24 months. Adjusting for age, body mass index, sex, race, and chemotherapy regimen, SII was a
significant mid-treatment predictor of both overall (adjusted HR (aHR) = 1.6, p < 0.0001; OS) and
progression-free (aHR = 1.3, p = 0.0072; PFS) survival. Among patients with mid-RT SII values above
the median (6.8), those receiving PEM (vs. ETO) had superior OS (p = 0.0002) and PFS (p = 0.0002).
Our secondary analysis suggests that SII is an informative mid-treatment marker of OS and PFS in
locally advanced non-squamous NSCLC.
Keywords: lung cancer; lymphopenia; neutrophilia; radiation; systemic immune-inflammation index
1. Introduction
Lung cancer ranks as the leading cause of cancer-related death in the United States and globally [1].
Non-small cell lung cancer (NSCLC) is the most common subtype, accounting for 85–90% of new
lung cancer diagnoses in the recent era. About one-third of patients with NSCLC present with locally
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advanced, non-metastatic disease [2,3]. Even with significant treatment advances, the outcomes for
unresectable stage III NSCLC remain poor, with many patients failing to achieve complete response or
long-term survival [4]. Only about 14% of stage IIIA and 5% of stage IIIB lung cancer patients survive
five years [5]. Thus, there is continued interest in identifying prognostic and predictive factors to
improve survival.
In recent years, there has been increased interest in systemic inflammation markers in oncology
for their prognostic and predictive potential. Systemic inflammation plays a prominent role in all
stages of tumor development and progression, impacting proliferation, survival, metastasis and
response to systemic therapies [6]. Continuous exposure to localized inflammatory states within the
premalignant tumor microenvironment underlies malignant transformation through intrinsic and
extrinsic pathways. Inflammation within these distinct spaces incites genetic mutations, promotes
angiogenesis, and increases tumor growth by suppressing anti-tumor immune responses [7].
The localization of inflammatory activity exposes pre-malignant cells to reactive oxygen species (ROS),
which in turn induces deleterious mutations to tumor suppressor genes and activates key oncogenes [8].
Malignant cells have also been implicated in the attraction and secretion of pro-inflammatory factors such
as IL-1, IL-6, IL-8, and TNFα, which promote further oncogenesis [9]. Specific to NSCLC, mutations on
the PTEN tumor suppressor gene triggers upregulation of HIF-1 and HIF-1-dependent transcription of
CXCR4, a chemokine receptor gene. This receptor is important in inflammation and cell survival within
the tumor microenvironment [10].
Changes in neutrophil, platelet, and lymphocyte counts act as indicators of inflammation
and/or impairment of tumor-targeted immune response. Neutrophils are leukocytes with numerous
pro-oncogenic properties that operate as critical mediators of localized inflammation in cancer.
An increased neutrophil count arises from increased secretion of hematopoietic cytokines, indicative of
a more aggressive nature of the tumor and helps to promote tumorigenesis and metastasis [11,12]. IL-1,
a leukocyte activation factor increased in inflammatory states, has been shown to raise systemic neutrophil
levels (neutrophilia), lower systemic lymphocyte counts (lymphopenia), and traffic neutrophils into
regions of localized inflammation [13]. Platelets, the acellular components of megakaryocytes, perform
a similar role in promoting tumorigenesis and angiogenesis through pro-inflammatory stimuli. Unlike
neutrophils and platelets, increased lymphocyte counts have been associated with tumor suppression,
apoptosis of cancer cells, and improved overall survival. Low pre-treatment lymphocyte count alone
has been shown to be an unfavorable prognostic factor in NSCLC and is associated with increased
lymphatic invasion and recurrence of NSCLC [14–19]. Radiotherapy (RT) directly destroys mature
circulating lymphocytes at radiation doses as low as <1 Gy, leading to a blunted systemic tumor-targeted
immune response [20–23].
The systemic immune-inflammation index (SII), defined as the product of neutrophil-to-lymphocyte
ratio (NLR) and platelet count (P), is a simple and noninvasive pretreatment prognostic indicator of tumor
advancement in NSCLC patients [24–31]. The presence of pre-treatment systemic inflammation, vis-à-vis
an increased baseline level of SII has been shown to be predictive of clinical outcomes in various cancers
including lung cancer [25,32–34]. This composite marker uses neutrophil, platelet, and lymphocyte
counts to quantify total body inflammation and reflects the balance of host inflammatory and immune
status [35]. It is highly reproducible, inexpensive, and widely available as part of routine complete
blood count (CBC) measurements, making it a promising prognostic marker. However, it is unclear if
SII also holds predictive potential for differentiating the effectiveness of chemotherapy. This question is
important for identifying patients who might best benefit from dynamic mid-treatment changes.
In this secondary analysis of data from the PROCLAIM study, we examined the prognostic
significance of SII values measured at mid-RT on overall (OS) and progression-free (PFS) survival.
We further aimed to test the hypothesis that pemetrexed + cisplatin (PEM) and etoposide + cisplatin
(ETO) would have different survival outcomes when stratified by high (above median) and low (below
median) values of SII at mid-RT.
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2. Materials and Methods
2.1. Study Design
Data for the current analysis were obtained from the PROCLAIM trial following approval by
Eli Lilly [36]. Briefly, PROCLAIM was a randomized open-label phase III clinical trial comparing
survival of patients with pathologically confirmed stage IIIA/B unresectable nonsquamous NSCLC,
who were administered PEM with concurrent thoracic RT followed by consolidation pemetrexed (arm A)
vs. ETO with concurrent thoracic RT followed by non-pemetrexed consolidation (arm B). Patients were
eligible if they were ≥18 years old and had an Eastern Cooperative Oncology Group (ECOG) PS of 0/1.
They also were required to have adequate organ and pulmonary function and evaluable disease on
computed tomography (CT) imaging or a measurable lesion according to Response Evaluation Criteria
in Solid Tumors v1.0 [37]. Targeted thoracic radiation doses ranging from 60–66 Gy (2 Gy/fraction
daily, 5 days per week) were delivered concurrently with day 1 of chemotherapy. For our analysis,
data used included pre-treatment CBC along with differential white count and weekly differential blood
count including neutrophil, platelet and lymphocyte count, which were used to compute SII values.
Mid-treatment SII was defined as values collected during weeks 3–4 of six weeks of RT, based on the
expected nadir value usually seen during this time period.
Among the 598 randomly assigned patients in PROCLAIM (301 arm A; 297 arm B), approximately
7% (18 arm A; 25 arm B) were not treated owing to unmet protocol entry criteria and/or patient/physician
decision, leaving 555 patients. Furthermore, those with metastatic disease (remaining in the study after
randomization), those with incomplete staging information, demographic details (race, sex), or RT
start or key laboratory dates, or those lacking follow-up times were excluded from the current analysis
(n = 7). Therefore, in our final analysis, 548 patients were included.
2.2. Statistical Analyses
Categorical variables were denoted as frequencies and percentages, while continuous variables
were reported as medians and interquartile ranges (IQR). SII values were transformed to logarithmic
scale to minimize skewness of the underlying distribution and referred to hereafter simply as SII
(unless otherwise indicated). Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) were
used as the estimated measure of survival risk and were computed using a Cox (proportional hazards)
regression model, accounting for the correlated structure of the data (i.e., multiple specific lab values
for some patients during the mid-point (week 3–4) time window) [38–40]. Demographic variables (age,
sex, and race) and treatment were included as model covariates. Models also were adjusted for body
mass index as a predisposing factor for inflammation [41].
OS was defined from the date of random assignment (baseline) to any cause of death. PFS was
defined from the date of random assignment (baseline) to the first date of documented objective
progressive disease or death. OS time was censored at the date the patient was last known to be alive if
not dead at the time of data lock. Similarly, PFS time was censored at the date of the last objective
progression-free disease assessment. For patients who received subsequent systemic anticancer
therapy before disease progression or death, PFS time was censored at the date of the last objective
progression-free disease assessment before the date of the subsequent systemic anticancer therapy.
To visualize survival times, product-limit estimates and corresponding Kaplan–Meier curves were
computed over all observations, regardless of independence [42].
p-values for linear trend were computed using a likelihood ratio test [43], while those for interaction
were based on the relative effect difference on the logarithmic scale [44]. Unknown values in the
predictor variables of a Cox regression model may unduly bias effect estimates if they are not completely
missing at random (CMAR). They also may reduce the ability to reject a false null hypothesis even
when the values are CMAR. An iterative (multi-stage) expectation-maximization (EM) algorithm with
nearest-neighbor adjustment and parametric imputation was used to account for missing baseline and
follow-up SII values, respectively [45,46].
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The parallel hazards assumption was not violated in our main Cox regression models [47].
SII values were initially analyzed as a continuous variable. Given that values were approximately
symmetrical after logarithmic transformation, with homogeneous risk within categories, we then
stratified the data by quartiles for the Cox regression analyses [48]. Potential outcome related factors
were carefully assessed for over-adjustment bias and unnecessary adjustment by our clinical team
prior to inclusion as covariates in our multivariable models [49].
Rounding was performed using the method of Holly and Whittemore [50]. Statistical significance
was defined as p < 0.05. SAS statistical software (version 9.4, SAS Institute Inc., Cary, NC, USA) was
used for all analyses.
3. Results
In our analyzed cohort, 548 patients received RT, with the majority being white (72%), male (61%),
and presenting with stage IIIB cancer (52%) (Table 1). The median age at baseline was 59 years (IQR = 14).
Patients were followed for a median of 24 months (IQR = 23). The baseline and mid-treatment median
values were as follows: 1.7 and 0.92 for neutrophil, 0.64 and −0.45 for lymphocyte, 5.7 and 5.4 for
platelet, and equally 6.8 and 6.8 for SII, respectively.
Table 1. Baseline (pre-radiotherapy) study characteristics (N = 548) ‡.
Characteristic n (%) or Median (IQR)
Age (y) 59 [14]
BMI 25 [5.6]
Sex
Male 332 (61)
Female 216 (39)
Race
White 392 (72)
Black 25 (5)
East Asian 115 (21)
Other 16 (3)
Stage
IIIA 264 (48)
IIIB 284 (52)
Treatment
Etoposide + Cisplatin (ETO) 268 (49)
Pemetrexed + Cisplatin (PEM) 280 (51)
‡ Among patients who received radiotherapy. y = Years. BMI = Body mass index IQR = Interquartile range.
Adjusting for age, BMI, sex, race, and treatment, baseline SII values were statistically significant
predictors of survival for the quartile 4 (Q4) vs. quartile 1 (Q1) (OS: aHR = 1.9, p < 0.0001; PFS: aHR = 1.5,
p = 0.0053). Similarly, at the mid-treatment point, Q4 had significantly worse OS and PFS outcomes
compared with Q1 (OS: aHR = 1.6, p < 0.0001; PFS: aHR = 1.3, p = 0.0072) (Table 2). Among patients
with mid-RT SII values above the median (Q3,4), those administered PEM vs. ETO had a 1.5-fold
(p = 0.0002) and 1.4-fold (p = 0.0002) lower aHR of dying or progressing during follow up, respectively
(Figures 1A and 2A). Clinically, this corresponds to 21 and 19 fewer patients on average dying or
progressing in the PEM arm. In contrast, the comparison of PEM vs. ETO among patients falling
in the lower (Q1,2) SII stratum was not significantly associated with OS (p = 0.79) or PFS (p = 0.068),
with corresponding p-for-interaction values of 0.023 and 0.23 (Figures 1B and 2B).
Stratifying the analysis by patients receiving ETO, those with mid-RT SII values >median vs.
≤median had a 1.7-fold (p < 0.0001) and 1.4-fold (p = 0.0020) higher aHR of dying or progressing
during follow up, respectively. However, aHRs for comparing the above and below median mid-RT
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values of SII were not statistically significant for either overall (1.2, p = 0.13) or progression-free
(1.1, p = 0.27) survival among those treated with PEM. The corresponding p-for-interaction values were
0.020 and 0.20.
While higher mid-RT lymphocyte (log-transformed) values (Q4 vs. Q1) corresponded to better
survival (OS: aHR = 0.78, 95%CI = 0.63–0.97); PFS: aHR = 0.72, 95%CI = 0.59–0.87) (not shown in
tables), the directional magnitude of the effect was less than the SII survival disadvantage observed for
SII (Q4 vs. Q1), as indicated by their wider CIs.
Table 2. Multivariable survival models by selected characteristics (N = 548) ‡.
Characteristic
Baseline
(Pre-RT)
Mid-RT
(Weeks 3–4 of RT)
OS PFS OS PFS
aHR (95%CI) ¥ aHR (95%CI) ¥ aHR (95%CI) ¥,† aHR (95%CI) ¥,†
Log (SII): Mean, SD 6.8, 0.76 6.8, 1.0
Percentile (25, 50, 75) (6.3, 6.8, 7.2) (6.1, 6.8, 7.4)
Q1 1.0 Referent 1.0 Referent 1.0 Referent 1.0 Referent
Q2 1.0 (0.75–1.5) 1.1 (0.80–1.4) 1.1 (0.86–1.3) 1.1 (0.93–1.4)
Q3 1.2 (0.88–1.7) 1.1 (0.84–1.5) 1.4 (1.1–1.8) 1.3 (1.1–1.6)
Q4 1.9 (1.4–2.6) 1.5 (1.1–2.1) 1.6 (1.3–2.1) 1.3 (1.1–1.6)
PTrend§ <0.0001 0.0081 <0.0001 0.0024
Age (y) 1.0 (0.9995–1.02) 1.0 (0.995–1.02) 1.01 (1.001–1.02) 1.0 (0.996–1.01)
BMI 0.99 (0.97–1.02) 0.99 (0.97–1.02) 1.0 (0.98–1.02) 0.99 (0.98–1.01)
Sex
Male 1.0 Referent 1.0 Referent 1.0 Referent 1.0 Referent
Female 0.72 (0.57–0.90) 0.79 (0.64–0.97) 0.71 (0.61–0.83) 0.81 (0.70–0.94)
Race
White 1.0 Referent 1.0 Referent 1.0 Referent 1.0 Referent
Black 1.2 (0.72–2.1) 1.3 (0.81–2.2) 0.95 (0.63–1.4) 1.2 (0.82–1.7)
East Asian 0.93 (0.69–1.3) 1.3 (1.02–1.7) 0.85 (0.70–1.04) 1.2 (1.05–1.5)
Other 1.1 (0.61–2.2) 1.0 (0.57–1.9) 1.2 (0.73–1.9) 1.0 (0.64–1.6)
Stage
IIIA 1.0 Referent 1.0 Referent 1.0 Referent 1.0 Referent
IIIB 1.3 (1.02–1.6) 1.3 (1.1–1.6) 1.4 (1.2–1.6) 1.4 (1.2–1.7)
Treatment
ETO 1.0 Referent 1.0 Referent 1.0 Referent 1.0 Referent
PEM 0.92 (0.74–1.1) 0.83 (0.68–1.01) 0.78 (0.67–0.92) 0.75 (0.65–0.87)
‡ Among patients who received RT. ¥ Proportional hazard model. † Accounting for correlated data structure at RT
mid-treatment point (weeks 3–4). § Likelihood ratio test for trend. aHR = Hazard ratio adjusted for variables in column 1.
BMI = Body mass index. CI = Confidence interval. ETO = Etoposide + cisplatin. Log = Logarithm. OS = Overall survival.
PEM = Pemetrexed + cisplatin. PFS = Progression-free survival. Q = Quartile. RT = Radiotherapy. SII = Systemic
immune-inflammation index. SD = Standard deviation. y = Years.
Int. J. Environ. Res. Public Health 2020, 17, 7995 6 of 13
Int. J. Environ. Res. Public Health 2020, 17, x  6 of 14 
 
 
 
Figure 1. Kaplan–Meier estimates of overall survival (pemetrexed + cisplatin vs. etoposide + cisplatin) 
for (A, top panel) mid-RT log SII > median and (B, bottom panel) mid-RT log SII ≤ median. Hazard 
ratios (HR) and 95% confidence intervals (CI) adjusted for age (years), body mass index (BMI), sex, 
and race. aHR = Adjusted HR. CI = Confidence interval. SII = Systemic immune-inflammation index. 
Figure 1. Kaplan–Meier estimates of overall survival (pemetrexed + cisplatin vs. etoposide + cisplatin)
for (A, top panel) mid-RT log SII > median and (B, bottom panel) mid-RT log SII ≤median. Hazard
ratios (HR) and 95% confidence intervals (CI) adjusted for age (years), body mass index (BMI), sex,
and race. aHR = Adjusted HR. CI = Confidence interval. SII = Systemic immune-inflammation index.
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Figure 2. Kaplan-Meier estimates of progression-free survival (pemetrexed + cisplatin vs. etoposide + 
cisplatin) for (A, top panel) mid-RT log SII > median and (B, bottom panel) mid-RT log SII ≤ median. 
Hazard ratios (HR) and 95% confidence intervals (CI) adjusted for age (years), body mass index (BMI), 
sex, and race. aHR = Adjusted HR. CI = Confidence interval. SII = Systemic immune-inflammation 
index. 
Stratifying the analysis by patients receiving ETO, those with mid-RT SII values >median vs. 
≤median had a 1.7-fold (p < 0.0001) and 1.4-fold (p = 0.0020) higher aHR of dying or progressing 
Figure 2. Kaplan-Meier estimates of progression-free survival (pemetrexed + cisplatin vs. etoposide +
cisplatin) for (A, top panel) mid-RT log SII > median and (B, bottom panel) mid-RT log SII ≤median.
Hazard ratios (HR) and 95% confidence intervals (CI) adjusted for age (years), body mass index (BMI), sex,
and race. aHR = Adjusted HR. CI = Confidence interval. SII = Systemic immune-inflammation index.
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4. Discussion
Our per-protocol analysis of patients at baseline who subsequently received concurrent
chemoradiation is consistent with the intent-to-treat findings of the PROCLAIM study, which did not
report an OS or PFS advantage of PEM vs. ETO [36]. However, because the incidence of grade 3 or 4
neutropenia in arm A of the PROCLAIM study was significantly lower than in arm B, we decided to
examine survival differences between treatment arms at the mid-point of RT, both adjusting for and
stratifying our results by SII (not specified as a priori endpoints in the protocol).
We found that patients in this cohort of locally advanced (stage IIIA/B) non-squamous NSCLC
experienced tumor progression and died sooner when they had mid-RT SII values falling into the 4th
vs. 1st quartile (Q4). Specifically, among participants with mid-RT SII values above the median (Q3,4),
those who received PEM vs. ETO had significantly better OS and PFS. We also observed a significant
interaction effect with respect to patients who received ETO. Those in this group progressed and died
sooner if they had mid-RT SII values above vs. below the median, in contrast to the PEM arm.
The last two to three decades have seen incremental modifications in RT, surgery, and systemic
therapy in the management of stage III NSCLC, with the current definitive treatment typically being
a combination of RT and a platinum-based chemotherapy agent, followed by immune checkpoint
inhibitor durvalumab. During definitive chemoradiation, the most used chemotherapy regimen in
the United States is weekly low-dose paclitaxel and carboplatin. An alternate regimen is another
platinum-based doublet like ETO. While a radiation dose of 60 Gy is the standard based on randomized
trial results, the preferred concurrent chemotherapy regimen with RT has not yet been established [51].
The multitargeted antifolate agent pemetrexed has been shown to have survival benefit in stage IV
adenocarcinoma of the lung [52,53]. In comparison, ETO has a less favorable toxicity profile (e.g.,
neutropenia, febrile neutropenia, anemia, and alopecia) than PEM doublets [54,55]. Etoposide also is
limited in therapeutic use by myelosuppression, particularly neutropenia [56]. However, a therapeutic
benefit for PEM (compared to ETO) was not observed for stage III non-squamous NSCLC based on
the recent PROCLAIM study [36,57,58]. Although not completely understood, especially given the
complex and interacting effect of RT on neutrophils, lymphocytes, and platelets, it is plausible that a
differential pharmacodynamic and survival profile exists between these two doublets, especially with
respect to the systemic inflammatory state.
Presently, there are no established prognostic markers aside from standard clinical information
for differentiating treatment in stage III NSCLC. During definitive treatment, patients undergo serial
CBCs to confirm adequate blood cell counts for continuation of treatment. While this blood work
contains a wealth of data regularly collected as a part of the treatment protocol, their prognostic
potential has not yet been fully realized. Inflammation in the body triggers lymphopenia, neutrophilia,
and thrombocytosis. Platelets bind internal cytokines with proinflammatory growth factors and directly
mediate tumorigenesis and angiogenesis [59–67]. Lymphocytes, which are reduced by inflammation,
typically play a role in destroying and disrupting cancer cell proliferation [68–72]. Neutrophils have
been shown to inhibit the T-cell lymphocyte response to tumors and are important in advancing tumor
growth and proliferation [73–77]. The mid-RT SII can represent the interactions between these various
markers of inflammation in a prognostic and predictive manner, although further studies delving into
the inflammatory pathways are needed.
Our observational analysis represents a nominal departure from the intent-to-treat design of
the PROCLAIM study and may be prone to residual bias and confounding by factors not adjusted
for in our study. However, our covariate adjusted pre-RT baseline results were comparable to those
reported by PROCLAIM. While our analysis attempted to account for the correlated structure of the
data during the mid-RT window, the possibility exists that the true underlying variance may have been
underestimated. An unspecified level of bias also may have been introduced by modeling missing
values, although such bias is generally believed to be less than the bias incurred by deleting these
data points. In our analysis, we used the median as the cutoff value for SII, given that there is no
established uniform cutoff value in literature for this marker [78]. In future studies, a consensus
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optimal cutoff value for SII should be determined from population-based studies, using appropriate
statistical methods to adjust for multiplicity. Furthermore, this was a hypothesis generating analysis
and needs further validation with additional studies.
The assessment of other potentially important indicators of tumor progression and survival
outcomes in lung cancer patients (e.g., modified Glasgow prognostic score, C-reactive protein to
albumin ratio, prognostic nutrition index, pretreatment advanced lung cancer inflammation index,
and procalcitonin) were considered to be beyond the scope of the current study but ideally would
be included in future comparative analyses [79]. Additionally, our analysis could not account for
thymidylate synthase expression, which is known to reduce sensitivity to pemetrexed and time to
treatment failure in NCSLC patients [80]. We also did not gauge the extent to which SII may have
been differentially influenced by hypercholesterolemia, concurrent infection, or the interaction with
various incidental drugs. However, such bias likely is nominal given the randomization of patients
in the PROCLAIM trial. An independent data monitoring committee evaluated nonblinded safety
information 6 months after the first 100 patients and then after all patients completed consolidation
chemotherapy. However, beyond this point, specific information about patient deaths (e.g., autopsy
report, exact causes) was not available in our analysis dataset.
The large sample size and systematic collection of data under the auspice of a prospective
randomized clinical trial with standardized assessment of laboratory measures across sites are key
strengths of this study. An important aspect of randomization is that outcome related factors will tend
to be balanced between arms. Our analyses were also less prone to biases that may arise with a single
center study.
5. Conclusions
The results from this study suggest that the systemic immune-inflammation index (SII) in
general is an informative baseline and mid-treatment marker of overall and progression-free survival.
Furthermore, we observed a statistically significant interaction of this index with the study drugs at
the mid-course of therapy. Further studies are needed to establish its value with the current standard
of consolidative immunotherapy following chemoradiation in stage III NSCLC. SII also may serve as a
surrogate endpoint in future clinical trials with the advantage of being able to assess the utility of a
new investigational compound in terms of months rather than years.
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